Who is sponsoring NCT00475072?

NCT00475072 is sponsored by Hoffmann-La Roche.

What condition does NCT00475072 study?

NCT00475072 studies Hepatitis C, Chronic.

What drugs are being tested in NCT00475072?

Interventions: peginterferon alfa-2a [Pegasys], ribavirin.

What is the status of NCT00475072?

NCT00475072 is currently COMPLETED.

Last reviewed 2016-10-29 · How we verify

An Open Label Study to Evaluate the Safety and Effect on Sustained Virological Response of PEGASYS Plus Ribavirin in Patients With Hemophilia A and Chronic Hepatitis C

NCT00475072 Phase 4 COMPLETED

This study will evaluate the efficacy and safety of PEGASYS plus ribavirin in male patients with hemophilia A and chronic hepatitis C. All patients will receive PEGASYS 180 micrograms s.c. weekly plus ribavirin 1000-1200mg p.o. daily (depending on body weight) for 48 weeks. Following treatment there will be a 24 week period of treatment-free follow-up. The anticipated time on study treatment is 3-12 months, and the target sample size is \<100 individuals.

Details

Lead sponsor	Hoffmann-La Roche
Phase	Phase 4
Status	COMPLETED
Enrolment	14
Start date	2003-06
Completion	2006-07

Conditions

Hepatitis C, Chronic

Interventions

peginterferon alfa-2a [Pegasys]
ribavirin

Primary outcomes

SVR — Week 72

Countries

Mexico